Takara Bio Inc
TF2
Company Profile
Business description
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
Contact
Nojihigashi 7-4-38 Kusatu
Shiga
Otsu520-0058
JPNT: +81 775656920
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
1,779
Stocks News & Analysis
stocks
Materially undervalued ASX tech share
Long reinvestment runway supports our thesis on ASX technology company.
stocks
For US software stocks, it’s been an AI bust, not a boom
Once-hot software names are lagging. Are they good buys?
stocks
Finding value in the Aussie mining sector
Is the mining sector overvalued? A new Morningstar report highlights pockets of value that remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,824.20 | 19.20 | -0.22% |
| CAC 40 | 7,963.26 | 3.59 | 0.05% |
| DAX 40 | 23,219.16 | 20.02 | -0.09% |
| Dow JONES (US) | 46,448.27 | 202.86 | 0.44% |
| FTSE 100 | 9,548.97 | 14.06 | 0.15% |
| HKSE | 25,894.55 | 178.05 | 0.69% |
| NASDAQ | 22,872.01 | 598.92 | 2.69% |
| Nikkei 225 | 48,659.52 | 33.64 | 0.07% |
| NZX 50 Index | 13,480.43 | 19.42 | -0.14% |
| S&P 500 | 6,705.12 | 102.13 | 1.55% |
| S&P/ASX 200 | 8,537.00 | 26.70 | -0.31% |
| SSE Composite Index | 3,870.02 | 33.26 | 0.87% |